3h1
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00006470)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, passive
CEACAM5 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- 3h1
- 3h1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00033748 | Phase 2 | Dec 1, 2001 | National Cancer Institute (NCI), University of Chicago |
| NCT00006470 | Phase 2 | Mar 1, 2001 | National Cancer Institute (NCI), Radiation Therapy Oncology Group, Temple University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2001 |
| Radiation Therapy Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2001 |
4 organizations
Page 1 / 1